INC Research has appointed several new senior leaders to strengthen its real world and late phase (RWLP) and global consulting offerings to the biopharma industry. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the company’s global consulting business to support customers at every stage of their product and portfolio development.

“Healthcare stakeholders are increasingly seeking real-world evidence to support regulatory, reimbursement and prescribing decisions,” said Christian Tucat, executive vice president, RWLP and global consulting, INC Research. “It’s never too early to have a commercial plan in drug development, and that’s why we’ve continued to grow our team. The leadership we’ve added in RWLP and global consulting have extensive industry connections and understand the complexities of late phase studies, moving new therapies from a controlled and experimental environment of a clinical trial to a real-world situation, and then to market. By beginning with the end in mind, we ensure we gain the right outcome for our sponsors as well as for patients, physicians, payers and regulators.”

The newly appointed members to INC’s RWLP and global consulting teams include:

James Featherstone, senior vice president, strategy consulting, has 25 years of experience in the healthcare industry. Dr. Featherstone served most recently as chief operations officer of Healthcare at Home, the UK’s largest home healthcare provider.

Janet Baldwin, vice president, real world and late phase, head of North America operations, has more than 30 years of drug development experience, working for both large pharma and CROs. For the past 10 years, she has served in a variety of roles, including head of late phase project management and analytics at Parexel.

Nathalie Doize, vice president, real world and late phase, head of Europe and Asia/Pacific operations, has more than 25 years of experience working in clinical research for both pharma and CROs. Prior to joining INC, she was vice president, global operations at Regist-Mapi.

Alastair MacDonald, executive director, real world and late phase, has 25 years of experience in the biopharmaceutical development sector. Prior to joining INC, he was global delivery director for medical evidence and observational research at Astra Zeneca.